Cancer-driver-agnostic targeting of amplified surface proteins identifies MPZL1 for selective CAR-T cell therapy

Abstract Most cancer therapies target genetic alterations driving tumor growth, but many drivers are undruggable or rare, limiting their therapeutic reach. Here, we demonstrate that amplified genes encoding cell surface proteins provide a rich, cancer-driver–agnostic source of targets. We identify MPZL1 (myelin protein zero–like 1), amplified in up to 75% of patients with certain solid tumor types, as abundantly expressed on the surface tumor cells across diverse cancer types while being largely absent from healthy tissues, offering a favorable therapeutic window. We develop a monoclonal antibody targeting MPZL1’s extracellular domain and engineer chimeric antigen receptor (CAR)-T cells that selectively eliminate MPZL1-positive cancer cells in vitro. These CAR-T cells exhibit antitumor activity in human xenograft, autochthonous mouse, and patient-derived tissue explant preclinical models. This work establishes MPZL1 as a viable CAR-T cell target and provides a generalizable framework for exploiting amplified cell surface receptors as broadly applicable therapeutic targets.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2026-09-10
DOI
https://doi.org/10.1038/s41467-026-77465-5
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Cancer-driver-agnostic targeting of amplified surface proteins identifies MPZL1 for selective CAR-T cell therapy

Luise Butthof, Judith Feucht, Lio Böse, Patrick Schmidt et al.
Nature Communications
CAR-T cell therapy research
article

Cancer-driver-agnostic targeting of amplified surface proteins identifies MPZL1 for selective CAR-T cell therapy

Luise Butthof, Judith Feucht, Lio Böse, Patrick Schmidt, Fee Klupp, Kai Breuhahn, Hendrik Wiethoff, Christos Patsis, Anna Berthel, Thomas Longerich, Meggy Suarez‐Carmona, Niels Halama, Darjus F. Tschaharganeh, Lena Wendler-Link, Peter Schirmacher, Dirk Jaeger, Marco Breinig, Melanie Grimm, Sonia Jimenez-vazquez, Matthias M. Gaida, Ilse Hofmann, Mara Mitstorfer, Martin Schneider, Markus Wallwiener
article en

Abstract

Abstract Most cancer therapies target genetic alterations driving tumor growth, but many drivers are undruggable or rare, limiting their therapeutic reach. Here, we demonstrate that amplified genes encoding cell surface proteins provide a rich, cancer-driver–agnostic source of targets. We identify MPZL1 (myelin protein zero–like 1), amplified in up to 75% of patients with certain solid tumor types, as abundantly expressed on the surface tumor cells across diverse cancer types while being largely absent from healthy tissues, offering a favorable therapeutic window. We develop a monoclonal antibody targeting MPZL1’s extracellular domain and engineer chimeric antigen receptor (CAR)-T cells that selectively eliminate MPZL1-positive cancer cells in vitro. These CAR-T cells exhibit antitumor activity in human xenograft, autochthonous mouse, and patient-derived tissue explant preclinical models. This work establishes MPZL1 as a viable CAR-T cell target and provides a generalizable framework for exploiting amplified cell surface receptors as broadly applicable therapeutic targets.

Nature CommunicationsVol. 17(1)
German Cancer Research Center (DE), Johannes Gutenberg University Mainz (DE), Heidelberg University (DE), University Hospital Heidelberg (DE), University Medical Center of the Johannes Gutenberg University Mainz (DE), National Center for Tumor Diseases (DE), University Children's Hospital Tübingen (DE), University of Tübingen (DE)
Good health and well-being
Openalex Percentile: Top 13%
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.